{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:06:56Z","timestamp":1788883616567,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omtn.2026.103027","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:29:18Z","timestamp":1786033758000},"page":"103027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["In the age of mRNA vaccines: Linear or circular mRNA?"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0580-5209","authenticated-orcid":false,"given":"Kenneth","family":"Lundstrom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103027_bib1","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103027_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 Vaccine: First Approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2026.103027_bib3","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector with Increased Translational Capacity and Biological Stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103027_bib4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omtn.2026.103027_bib5","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.omtn.2026.103027_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","article-title":"Circular RNA vaccine in disease prevention and treatment","volume":"8","author":"Niu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omtn.2026.103027_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2026.102954","article-title":"Comparative analysis of expression, immunogenicity, and safety profiles between linear and circular RNA vaccine platforms","volume":"37","author":"Lee","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103027_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.103027_bib9","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1016\/j.cell.2022.06.001","article-title":"Circular RNAs: Characterization, cellular roles, and applications","volume":"185","author":"Liu","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103027_bib10","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","article-title":"Circular RNA vaccines against SARS-CoV-2 and emerging variants","volume":"185","author":"Qu","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103027_bib11","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.1109\/JBHI.2025.3561197","article-title":"Integrating transformer and graph attention network for circRNA-miRNA interaction prediction","volume":"29","author":"Wei","year":"2025","journal-title":"IEEE J. Biomed. Health Inform."},{"key":"10.1016\/j.omtn.2026.103027_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114993","article-title":"mRNA: A promising platform for cancer immunotherapy","volume":"199","author":"Kong","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2026.103027_bib13","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.7150\/thno.77350","article-title":"Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.omtn.2026.103027_bib14","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2026.103027_bib15","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.ymthe.2025.03.060","article-title":"The advent of clinical self-amplifying RNA vaccines","volume":"33","author":"Casmil","year":"2025","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:09:26Z","timestamp":1788880166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126001988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2162253126001988"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103027","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In the age of mRNA vaccines: Linear or circular mRNA?","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103027"}}